Lumexa Imaging Announces Second Quarter 2026 Results
Lumexa Imaging Holdings, Inc. (LMRI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lumexa Imaging Announces Second Quarter 2026 Results RALEIGH, N. C., August 12, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, and updated it
How this was made
The 30-second read
Why it matters
The most tradable element is the guidance package: reiterated revenue and Adjusted EPS, plus a narrowed Adjusted EBITDA range, alongside improved GAAP profitability in the quarter.
Market read
Traders can update models using the reiterated revenue and Adjusted EPS ranges and the narrowed Adjusted EBITDA guidance band, plus the quarter’s GAAP and Adjusted profitability metrics.
What to watch
Investors may focus on same-center advanced volume growth deceleration (consolidated 5.2% vs prior period) and the JV/center ramp execution risk implied by the expansion narrative.
Background
The SEC 8-K includes Lumexa Imaging’s Q2 2026 operating results and an updated full-year 2026 outlook.
Ticker impact
Lumexa Imaging reported 2Q26 results and updated full-year 2026 guidance, including revenue range $1.045B to $1.097B and narrowed Adjusted EBITDA to $235M to $241M.
Likely supportive for the stock versus prior expectations if the market views the narrowed range and reiterated revenue as credible; magnitude depends on how investors compare to consensus.
The filing includes concrete quarterly performance (revenue, net income vs loss, Adjusted EBITDA) plus explicit full-year guidance changes (EBITDA range narrowed, revenue and Adjusted EPS reiterated).
Market effects
Outpatient imaging providers may see read-across on demand durability and center expansion economics, but this is company-specific guidance.
No specific regional demand or policy change is disclosed beyond company operations.
Limited, as the news is US outpatient imaging operations and guidance.
Counterpoint
The Adjusted EBITDA margin is slightly lower (21.4% vs 22.4%), and the guidance includes added public company costs, which could temper quality of earnings.
Key entities
- companyLumexa Imaging Holdings, Inc.
Outpatient imaging services provider reporting Q2 2026 results and updating full-year 2026 guidance in an SEC 8-K.
- partnerHospital for Special Surgery (HSS)
Named as a joint venture partner in the company’s operational highlights.
